COPENHAGEN--(BUSINESS WIRE)--New clinical data being presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark will highlight recent observations of the hepatitis C virus (HCV) protease inhibitor telaprevir in the treatment of multiple HCV genotypes, and the early safety and antiviral profile of the HCV polymerase inhibitor VCH-222. In addition, sustained viral response (SVR) rates from the PROVE 3 clinical trial of telaprevir in patients who failed prior HCV therapy will be reviewed at a late breaker oral presentation on Saturday, April 25, 2009. These data will be the subject of a separate announcement in accordance with EASL publication rules. Telaprevir is one of the most advanced of a new class of specifically targeted antiviral therapies for hepatitis C (STAT-C), and is being developed by Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in collaboration with Tibotec and Mitsubishi Tanabe Pharma. Vertex recently acquired VCH-222 along with other early-stage compounds as part of its acquisition of ViroChem Pharma Inc.
